KOL Bulletin: Sanofi's Lunskeimig Shows Promise in Respiratory Diseases but Faces Challenges Against Dupixent and Anti-TSLP Competitors

Sanofi's lunsekimig, a bispecific Nanobody targeting TSLP and IL-13, met primary and key secondary endpoints in phase 2b AIRCULES study for moderate-to-severe asthma, reducing exacerbations and improving lung function.1 2 3 4

In the phase 2a DUET study, lunsekimig met primary endpoint (nasal polyp score) and key secondary endpoints (nasal congestion, LMK-CT score) in chronic rhinosinusitis with nasal polyps (CRSwNP).2 3 4 5

Lunsekimig failed primary endpoint in phase 2 VELVET study for atopic dermatitis/eczema, though some secondary improvements observed; well-tolerated across studies.2 3 4 5 6

KOL views indicate lunsekimig works but has much to prove to surpass Dupixent, Tezspire, and other anti-TSLP drugs.1

Results announced April 7, 2026; lunsekimig advancing to phase 2/3 in asthma and COPD.2 5

Sanofi seeks successors to Dupixent amid patent expiry pressures.3 5